The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Infliximab and Biosimilar-Global Market Insights and Sales Trends 2025
Synopsis
Infliximab (trade names Remicade among others) is a chimeric monoclonal antibody biologic drug that works against tumor necrosis factor alpha (TNF-α) and is used to treat autoimmune diseases.
The global Infliximab and Biosimilar market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Infliximab and Biosimilar in various end use industries. The expanding demands from the Crohn's Disease, Pediatric Crohn's Disease, Ulcerative Colitis and Rheumatoid Arthritis, are propelling Infliximab and Biosimilar market. Infliximab, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Infliximab-dyyb segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Infliximab and Biosimilar, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Infliximab and Biosimilar market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Infliximab and Biosimilar market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Infliximab and Biosimilar sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Infliximab and Biosimilar covered in this report include Janssen Biotech, Merck and Co. and Pfizer, etc.
The global Infliximab and Biosimilar market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Janssen Biotech
Merck and Co.
Pfizer
Global Infliximab and Biosimilar market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Infliximab and Biosimilar market, Segment by Type:
Infliximab
Infliximab-dyyb
Infliximab-abda
Global Infliximab and Biosimilar market, by Application
Crohn's Disease
Pediatric Crohn's Disease
Ulcerative Colitis
Rheumatoid Arthritis
Ankylosing Spondylitis
Psoriatic Arthritis
Plaque Psoriasis
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Infliximab and Biosimilar manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Infliximab and Biosimilar in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
Infliximab (trade names Remicade among others) is a chimeric monoclonal antibody biologic drug that works against tumor necrosis factor alpha (TNF-α) and is used to treat autoimmune diseases.
The global Infliximab and Biosimilar market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Infliximab and Biosimilar in various end use industries. The expanding demands from the Crohn's Disease, Pediatric Crohn's Disease, Ulcerative Colitis and Rheumatoid Arthritis, are propelling Infliximab and Biosimilar market. Infliximab, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Infliximab-dyyb segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Infliximab and Biosimilar, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Infliximab and Biosimilar market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Infliximab and Biosimilar market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Infliximab and Biosimilar sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Infliximab and Biosimilar covered in this report include Janssen Biotech, Merck and Co. and Pfizer, etc.
The global Infliximab and Biosimilar market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Janssen Biotech
Merck and Co.
Pfizer
Global Infliximab and Biosimilar market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Infliximab and Biosimilar market, Segment by Type:
Infliximab
Infliximab-dyyb
Infliximab-abda
Global Infliximab and Biosimilar market, by Application
Crohn's Disease
Pediatric Crohn's Disease
Ulcerative Colitis
Rheumatoid Arthritis
Ankylosing Spondylitis
Psoriatic Arthritis
Plaque Psoriasis
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Infliximab and Biosimilar manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Infliximab and Biosimilar in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
Index1 Infliximab and Biosimilar Market Overview
1.1 Infliximab and Biosimilar Product Overview
1.2 Infliximab and Biosimilar Market Segment by Type
1.2.1 Infliximab
1.2.2 Infliximab-dyyb
1.2.3 Infliximab-abda
1.3 Global Infliximab and Biosimilar Market Size by Type
1.3.1 Global Infliximab and Biosimilar Market Size Overview by Type (2018-2029)
1.3.2 Global Infliximab and Biosimilar Historic Market Size Review by Type (2018-2023)
1.3.3 Global Infliximab and Biosimilar Forecasted Market Size by Type (2024-2029)
1.4 Key Regions Market Size Segment by Type
1.4.1 North America Infliximab and Biosimilar Sales Breakdown by Type (2018-2023)
1.4.2 Europe Infliximab and Biosimilar Sales Breakdown by Type (2018-2023)
1.4.3 Asia-Pacific Infliximab and Biosimilar Sales Breakdown by Type (2018-2023)
1.4.4 Latin America Infliximab and Biosimilar Sales Breakdown by Type (2018-2023)
1.4.5 Middle East and Africa Infliximab and Biosimilar Sales Breakdown by Type (2018-2023)
2 Global Infliximab and Biosimilar Market Competition by Company
2.1 Global Top Players by Infliximab and Biosimilar Sales (2018-2023)
2.2 Global Top Players by Infliximab and Biosimilar Revenue (2018-2023)
2.3 Global Top Players by Infliximab and Biosimilar Price (2018-2023)
2.4 Global Top Manufacturers Infliximab and Biosimilar Manufacturing Base Distribution, Sales Area, Product Type
2.5 Infliximab and Biosimilar Market Competitive Situation and Trends
2.5.1 Infliximab and Biosimilar Market Concentration Rate (2018-2023)
2.5.2 Global 5 and 10 Largest Manufacturers by Infliximab and Biosimilar Sales and Revenue in 2022
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Infliximab and Biosimilar as of 2022)
2.7 Date of Key Manufacturers Enter into Infliximab and Biosimilar Market
2.8 Key Manufacturers Infliximab and Biosimilar Product Offered
2.9 Mergers & Acquisitions, Expansion
3 Infliximab and Biosimilar Status and Outlook by Region
3.1 Global Infliximab and Biosimilar Market Size and CAGR by Region: 2018 VS 2022 VS 2029
3.2 Global Infliximab and Biosimilar Historic Market Size by Region
3.2.1 Global Infliximab and Biosimilar Sales in Volume by Region (2018-2023)
3.2.2 Global Infliximab and Biosimilar Sales in Value by Region (2018-2023)
3.2.3 Global Infliximab and Biosimilar Sales (Volume & Value) Price and Gross Margin (2018-2023)
3.3 Global Infliximab and Biosimilar Forecasted Market Size by Region
3.3.1 Global Infliximab and Biosimilar Sales in Volume by Region (2024-2029)
3.3.2 Global Infliximab and Biosimilar Sales in Value by Region (2024-2029)
3.3.3 Global Infliximab and Biosimilar Sales (Volume & Value), Price and Gross Margin (2024-2029)
4 Global Infliximab and Biosimilar by Application
4.1 Infliximab and Biosimilar Market Segment by Application
4.1.1 Crohn's Disease
4.1.2 Pediatric Crohn's Disease
4.1.3 Ulcerative Colitis
4.1.4 Rheumatoid Arthritis
4.1.5 Ankylosing Spondylitis
4.1.6 Psoriatic Arthritis
4.1.7 Plaque Psoriasis
4.2 Global Infliximab and Biosimilar Market Size by Application
4.2.1 Global Infliximab and Biosimilar Market Size Overview by Application (2018-2029)
4.2.2 Global Infliximab and Biosimilar Historic Market Size Review by Application (2018-2023)
4.2.3 Global Infliximab and Biosimilar Forecasted Market Size by Application (2024-2029)
4.3 Key Regions Market Size Segment by Application
4.3.1 North America Infliximab and Biosimilar Sales Breakdown by Application (2018-2023)
4.3.2 Europe Infliximab and Biosimilar Sales Breakdown by Application (2018-2023)
4.3.3 Asia-Pacific Infliximab and Biosimilar Sales Breakdown by Application (2018-2023)
4.3.4 Latin America Infliximab and Biosimilar Sales Breakdown by Application (2018-2023)
4.3.5 Middle East and Africa Infliximab and Biosimilar Sales Breakdown by Application (2018-2023)
5 North America Infliximab and Biosimilar by Country
5.1 North America Infliximab and Biosimilar Historic Market Size by Country
5.1.1 North America Infliximab and Biosimilar Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
5.1.2 North America Infliximab and Biosimilar Sales in Volume by Country (2018-2023)
5.1.3 North America Infliximab and Biosimilar Sales in Value by Country (2018-2023)
5.2 North America Infliximab and Biosimilar Forecasted Market Size by Country
5.2.1 North America Infliximab and Biosimilar Sales in Volume by Country (2024-2029)
5.2.2 North America Infliximab and Biosimilar Sales in Value by Country (2024-2029)
6 Europe Infliximab and Biosimilar by Country
6.1 Europe Infliximab and Biosimilar Historic Market Size by Country
6.1.1 Europe Infliximab and Biosimilar Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
6.1.2 Europe Infliximab and Biosimilar Sales in Volume by Country (2018-2023)
6.1.3 Europe Infliximab and Biosimilar Sales in Value by Country (2018-2023)
6.2 Europe Infliximab and Biosimilar Forecasted Market Size by Country
6.2.1 Europe Infliximab and Biosimilar Sales in Volume by Country (2024-2029)
6.2.2 Europe Infliximab and Biosimilar Sales in Value by Country (2024-2029)
7 Asia-Pacific Infliximab and Biosimilar by Region
7.1 Asia-Pacific Infliximab and Biosimilar Historic Market Size by Region
7.1.1 Asia-Pacific Infliximab and Biosimilar Market Size Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2029
7.1.2 Asia-Pacific Infliximab and Biosimilar Sales in Volume by Region (2018-2023)
7.1.3 Asia-Pacific Infliximab and Biosimilar Sales in Value by Region (2018-2023)
7.2 Asia-Pacific Infliximab and Biosimilar Forecasted Market Size by Region
7.2.1 Asia-Pacific Infliximab and Biosimilar Sales in Volume by Region (2024-2029)
7.2.2 Asia-Pacific Infliximab and Biosimilar Sales in Value by Region (2024-2029)
8 Latin America Infliximab and Biosimilar by Country
8.1 Latin America Infliximab and Biosimilar Historic Market Size by Country
8.1.1 Latin America Infliximab and Biosimilar Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
8.1.2 Latin America Infliximab and Biosimilar Sales in Volume by Country (2018-2023)
8.1.3 Latin America Infliximab and Biosimilar Sales in Value by Country (2018-2023)
8.2 Latin America Infliximab and Biosimilar Forecasted Market Size by Country
8.2.1 Latin America Infliximab and Biosimilar Sales in Volume by Country (2024-2029)
8.2.2 Latin America Infliximab and Biosimilar Sales in Value by Country (2024-2029)
9 Middle East and Africa Infliximab and Biosimilar by Country
9.1 Middle East and Africa Infliximab and Biosimilar Historic Market Size by Country
9.1.1 Middle East and Africa Infliximab and Biosimilar Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
9.1.2 Middle East and Africa Infliximab and Biosimilar Sales in Volume by Country (2018-2023)
9.1.3 Middle East and Africa Infliximab and Biosimilar Sales in Value by Country (2018-2023)
9.2 Middle East and Africa Infliximab and Biosimilar Forecasted Market Size by Country
9.2.1 Middle East and Africa Infliximab and Biosimilar Sales in Volume by Country (2024-2029)
9.2.2 Middle East and Africa Infliximab and Biosimilar Sales in Value by Country (2024-2029)
10 Company Profiles
10.1 Janssen Biotech
10.1.1 Janssen Biotech Company Information
10.1.2 Janssen Biotech Introduction and Business Overview
10.1.3 Janssen Biotech Infliximab and Biosimilar Sales, Revenue and Gross Margin (2018-2023)
10.1.4 Janssen Biotech Infliximab and Biosimilar Products Offered
10.1.5 Janssen Biotech Recent Development
10.2 Merck and Co.
10.2.1 Merck and Co. Company Information
10.2.2 Merck and Co. Introduction and Business Overview
10.2.3 Merck and Co. Infliximab and Biosimilar Sales, Revenue and Gross Margin (2018-2023)
10.2.4 Merck and Co. Infliximab and Biosimilar Products Offered
10.2.5 Merck and Co. Recent Development
10.3 Pfizer
10.3.1 Pfizer Company Information
10.3.2 Pfizer Introduction and Business Overview
10.3.3 Pfizer Infliximab and Biosimilar Sales, Revenue and Gross Margin (2018-2023)
10.3.4 Pfizer Infliximab and Biosimilar Products Offered
10.3.5 Pfizer Recent Development
11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 Infliximab and Biosimilar Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 Infliximab and Biosimilar Industrial Chain Analysis
11.4 Infliximab and Biosimilar Market Dynamics
11.4.1 Infliximab and Biosimilar Industry Trends
11.4.2 Infliximab and Biosimilar Market Drivers
11.4.3 Infliximab and Biosimilar Market Challenges
11.4.4 Infliximab and Biosimilar Market Restraints
12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 Infliximab and Biosimilar Distributors
12.3 Infliximab and Biosimilar Downstream Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
